Evommune, Inc.

FWP supplemental

Price $16.00 · 9,375,000 shares · Gross proceeds $150,000,000

Evommune, Inc. has priced its initial public offering (IPO) of 9,375,000 shares of common stock at $16.00 per share, with an additional 1,406,250 shares available under the underwriters' option. The offering, led by Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor, is expected to raise $150 million in gross proceeds. The shares will trade on the NYSE under the symbol 'EVMN' starting November 6, 2025.

424B4 priced

Price $16.00 · 9,375,000 shares · Gross proceeds $150,000,000

Evommune, Inc. is conducting its initial public offering (IPO) of 9,375,000 shares of common stock at $16.00 per share, with gross proceeds of $150 million. The company, a clinical-stage biotechnology firm, focuses on developing therapies for chronic inflammatory diseases like chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). Two product candidates, EVO756 and EVO301, are in Phase 2 trials, targeting MRGPRX2 and IL-18 pathways, respectively. The offering is underwritten by Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor.

CERT inactive

Evommune, Inc. is registering its common stock for trading on the New York Stock Exchange, as outlined in its previous 8-A12B filing. The current CERT filing appears to be a placeholder or incomplete submission, with no visible updates or changes from the prior 8-A12B form. The company's registration statement references its S-1 prospectus, indicating preparation for an IPO, but no new details are provided in the current filing.

8-A12B effective

Evommune, Inc. has filed Form 8-A12B to register its common stock for listing on the New York Stock Exchange. The filing incorporates by reference the company's earlier Registration Statement on Form S-1 (File No. 333-290793), which includes details about the proposed initial public offering (IPO). The company, a clinical-stage biotechnology firm, aims to advance therapies targeting chronic inflammatory diseases. The 8-A12B form does not include exhibits, as the securities are not registered under Section 12(g) of the Exchange Act.

FWP supplemental

Range $15.00 to $17.00 · 9,375,000 shares

Evommune, Inc. has initiated its initial public offering (IPO) with a proposed offering of 9,375,000 shares of common stock at an expected price range of $15.00 to $17.00 per share. The company, a clinical-stage biotechnology firm focused on chronic inflammatory diseases, plans to list on the NYSE under the symbol 'EVMN.' The registration statement is set to become effective on November 5, 2025, contingent on SEC procedures. Underwriters include Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor.

S-1/A amended

Range $15.00 to $17.00 · 9,375,000 shares

Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, including chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The company is conducting Phase 2 trials for two product candidates, EVO756 and EVO301, with EVO756 showing promising results in reducing symptoms of CSU and chronic inducible urticaria (CIndU). The S-1/A filing reflects updates to the initial public offering (IPO), including revised clinical trial data, underwriter details, and expanded disclosures about the company's financial and operational status. The IPO is contingent on NYSE listing approval, with an expected price range of $15.00 to $17.00 per share.

S-1 filed

Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases, including chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The company is conducting Phase 2 trials for two product candidates, EVO756 and EVO301, which target key drivers of inflammation. This is Evommune's initial public offering (IPO), with shares expected to be listed on the NYSE under the symbol 'EVMN'. The offering includes details on pricing, underwriters, and risks associated with clinical trials and regulatory approvals.

DRS/A amended

Evommune, Inc. is conducting its initial public offering (IPO) for      shares of common stock, with an expected price range of $   to $   per share. The company is a clinical-stage biotechnology firm developing therapies for chronic inflammatory diseases, including CSU, AD, and UC. Two product candidates, EVO756 and EVO301, are in Phase 2 trials, with EVO756 showing promising results in reducing symptoms of chronic urticaria and demonstrating target engagement. The IPO is contingent on NYSE listing approval, and the company is classified as an emerging growth company with reduced reporting requirements.

DRS/A amended

Evommune, Inc. is conducting its initial public offering (IPO) for common stock, aiming to raise capital to advance its clinical-stage biotechnology programs targeting chronic inflammatory diseases. The company is developing two key product candidates, EVO756 and EVO301, in Phase 2 trials for conditions like chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The filing highlights updated clinical trial data, including positive results from a Phase 2 CIndU trial for EVO756 and plans for Phase 2b trials in CSU and AD. The IPO is contingent on stock exchange listing approval and includes underwriters Morgan Stanley, Leerink Partners, and Evercore ISI.

DRS/A amended

Evommune, Inc. is conducting its initial public offering (IPO) to raise capital for its clinical-stage biotechnology programs targeting chronic inflammatory diseases. The company is advancing two product candidates, EVO756 and EVO301, in Phase 2 trials for conditions like chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The IPO involves offering shares of common stock, with underwriters including Morgan Stanley, Leerink Partners, and Evercore ISI. The filing highlights progress in clinical trials, including positive Phase 2 data for EVO756 in chronic inducible urticaria (CIndU) and plans for future trials in AD and UC.

DRS filed

Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases. The company is conducting Phase 2 trials for two product candidates, EVO756 and EVO301, targeting conditions like chronic spontaneous urticaria, atopic dermatitis, and inflammatory bowel diseases. This filing represents Evommune's initial public offering (IPO) of common stock, with underwriters including Morgan Stanley, Leerink Partners, and Evercore ISI. The company is classified as an emerging growth company and a smaller reporting company.